Cabaletta Bio (NASDAQ:CABA – Get Free Report) and CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Volatility and Risk
Cabaletta Bio has a beta of 3.18, indicating that its share price is 218% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
Profitability
This table compares Cabaletta Bio and CollPlant Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cabaletta Bio | N/A | -131.58% | -96.46% |
| CollPlant Biotechnologies | -353.70% | -161.69% | -109.44% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cabaletta Bio | 1 | 1 | 5 | 0 | 2.57 |
| CollPlant Biotechnologies | 1 | 1 | 1 | 0 | 2.00 |
Cabaletta Bio presently has a consensus target price of $15.50, suggesting a potential upside of 310.05%. CollPlant Biotechnologies has a consensus target price of $11.50, suggesting a potential upside of 2,760.70%. Given CollPlant Biotechnologies’ higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Cabaletta Bio.
Valuation and Earnings
This table compares Cabaletta Bio and CollPlant Biotechnologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cabaletta Bio | N/A | N/A | -$167.86 million | ($1.96) | -1.93 |
| CollPlant Biotechnologies | $2.37 million | 2.44 | -$11.49 million | ($1.35) | -0.30 |
CollPlant Biotechnologies has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
CollPlant Biotechnologies beats Cabaletta Bio on 7 of the 13 factors compared between the two stocks.
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.
